<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00260351</url>
  </required_header>
  <id_info>
    <org_study_id>RAB28</org_study_id>
    <nct_id>NCT00260351</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Verorab™ in Indian Population</brief_title>
  <official_title>Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To demonstrate that rabies vaccine administered according to the Thai Red Cross,&#xD;
           (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according&#xD;
           to the ESSEN IM regimen in terms of Geometric Mean Titers (GMTs) at D28, in subjects&#xD;
           with a WHO category III rabies exposure,or,&#xD;
&#xD;
        -  To demonstrate that Rabies vaccine administered according to the ZAGREB-IM regimen&#xD;
           (2-1-1) is not inferior to Rabies vaccine administered according to the ESSEN IM regimen&#xD;
           in terms of GMTs at D28, in subjects with a WHO category III rabies exposure.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To describe the immunogenicity profile of each regimen&#xD;
&#xD;
        2. To assess the safety of the vaccine in each group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: To provide information concerning the immune response of Purified Verocell Rabies Vaccine</measure>
    <time_frame>6 months post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on Thai Red Cross, TRC-ID regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on Zagreb-IM regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on Essen-IM regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Verocell Rabies Vaccine</intervention_name>
    <description>0.1 mL, ID (TRC regimen)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>PVRV, VERORAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Verocell Rabies Vaccine</intervention_name>
    <description>0.5 mL, IM (ZAGREB regimen)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>PVRV, VERORAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Verocell Rabies Vaccine</intervention_name>
    <description>0.5 mL, IM (ESSEN regimen)</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>PVRV, VERORAB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with WHO category III rabies exposure&#xD;
&#xD;
          -  Subject aged at least 2 years old (day of second birthday)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject unable to comply with the follow-up schedule of the protocol&#xD;
&#xD;
          -  Delayed post-exposure treatment (&gt;72 hours between incident and treatment&#xD;
&#xD;
          -  Subject bitten by an observable animal at the inclusion visit&#xD;
&#xD;
          -  Subject with immune-compromised or underlying diseases which may lead to inferior&#xD;
             immune response&#xD;
&#xD;
          -  Subject with known pregnancy at the time of inclusion&#xD;
&#xD;
          -  Subject enrolled or scheduled to be enrolled in another clinical study.&#xD;
&#xD;
          -  Subject with acute febrile illness/ axillary temperature &gt; 37.5 degree celsius&#xD;
&#xD;
          -  Subject in whom blood sampling will be difficult.&#xD;
&#xD;
          -  Subject receiving chloroquine or other anti-malarial treatment&#xD;
&#xD;
          -  Subject receiving immunosuppressive therapy, other immune-modifying drug or cytotoxic&#xD;
             drugs&#xD;
&#xD;
          -  Subject with known chronic illnesses (ie. heart, lung, kidney, liver) including&#xD;
             immunosuppressive diseases (cancer, HIV, etc.)&#xD;
&#xD;
          -  Previous rabies immunization&#xD;
&#xD;
          -  Subject having received any vaccine within the previous 30 days, except tetanus toxoid&#xD;
             and tetanus immunoglobulin&#xD;
&#xD;
          -  Subject with clinical signs of rabies&#xD;
&#xD;
          -  Subject with known allergy to vaccine components (e.g. neomycin)&#xD;
&#xD;
          -  Subject who received blood and/or plasma transfusion within the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calcutta</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>November 29, 2005</study_first_submitted>
  <study_first_submitted_qc>November 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rabies;</keyword>
  <keyword>rabies post-exposure;</keyword>
  <keyword>category III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

